Biotech · Private company

Tris Pharma, Inc.

Track this companyFree. Adds Tris Pharma, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials151 recruiting or active

Pipeline programs33From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline33

AMPH ER Tab 5, 10, 15 and 20 mgPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
amphetamine extended-release oral suspension, 2.5 mg/mLPhase 3 · Attention Deficit Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026
CebranopadolPhase 3 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 200 ugPhase 3 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 400 ugPhase 3 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
Oxycodone IRPhase 3 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
TRI102Phase 3 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
Amphetamine Extended Release (ER) Tablet 20 mgPhase 2 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol (GRT6005) High-Dose RangePhase 2 · Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneeClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol (GRT6005) Low-Dose RangePhase 2 · Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneeClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 100 µgPhase 2 · Chronic PainClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 300 µgPhase 2 · Chronic PainClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 600 µgPhase 2 · Chronic PainClinicalTrials.gov · fetched Nov 12, 2026
GRT6005Phase 2 · Post Operative PainClinicalTrials.gov · fetched Nov 12, 2026
MorphinePhase 2 · Post Operative PainClinicalTrials.gov · fetched Nov 12, 2026
Oxycodone CRPhase 2 · Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneeClinicalTrials.gov · fetched Nov 12, 2026
PregabalinPhase 2 · Chronic PainClinicalTrials.gov · fetched Nov 12, 2026
100 μg cebranopadolPhase 1 · Prolonged QTc IntervalClinicalTrials.gov · fetched Nov 12, 2026
200 μg cebranopadolPhase 1 · Prolonged QTc IntervalClinicalTrials.gov · fetched Nov 12, 2026
400 mg MoxifloxacinPhase 1 · Prolonged QTc IntervalClinicalTrials.gov · fetched Nov 12, 2026
400 μg cebranopadolPhase 1 · Prolonged QTc IntervalClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 1000 µgPhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 200 μg tabletPhase 1 · PharmacokineticClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol 600 µgPhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol- 1000ugPhase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol- 600 ugPhase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Cebranopadol- 800ugPhase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Oxycodone 40 mgPhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
Tramadol 600 mgPhase 1 · Human Abuse PotentialClinicalTrials.gov · fetched Nov 12, 2026
Treatment A:Phase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Treatment BPhase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Treatment CPhase 1 · Abuse, DrugClinicalTrials.gov · fetched Nov 12, 2026
Amphetamine Extended Release Suspension [Dyanavel]Attention Deficit Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials15

EEG Biomarkers for ADHD Stimulant TreatmentPHASE4 · NOT_YET_RECRUITING · started Sep 15, 2026ClinicalTrials.gov NCT07650643 · fetched Nov 12, 2026
A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyPHASE3 · COMPLETED · started Sep 3, 2024ClinicalTrials.gov NCT06545097 · fetched Nov 12, 2026
A Study of Cebranopadol for the Treatment of Acute Pain After BunionectomyPHASE3 · COMPLETED · started Jul 18, 2024ClinicalTrials.gov NCT06423703 · fetched Nov 12, 2026
A Study to Assess the Abuse Potential of Intranasal CebranopadolPHASE1 · COMPLETED · started Jun 28, 2024ClinicalTrials.gov NCT06453265 · fetched Nov 12, 2026
Assessment of Abuse Potential of Cebranopadol in HumansPHASE1 · COMPLETED · started Mar 28, 2022ClinicalTrials.gov NCT05256108 · fetched Nov 12, 2026
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)PHASE2 · COMPLETED · started Oct 1, 2019ClinicalTrials.gov NCT04027361 · fetched Nov 12, 2026
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHDPHASE3 · COMPLETED · started Feb 6, 2019ClinicalTrials.gov NCT03834766 · fetched Nov 12, 2026
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 YearsPHASE4 · COMPLETED · started May 7, 2018ClinicalTrials.gov NCT03610464 · fetched Nov 12, 2026
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School StudyPHASE3 · COMPLETED · started Feb 11, 2017ClinicalTrials.gov NCT03088267 · fetched Nov 12, 2026
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)PHASE3 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02083783 · fetched Nov 12, 2026
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesPHASE2 · COMPLETED · started Sep 27, 2013ClinicalTrials.gov NCT01939366 · fetched Nov 12, 2026
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy SubjectsPHASE1 · COMPLETED · started Jul 10, 2013ClinicalTrials.gov NCT03958123 · fetched Nov 12, 2026
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of CebranopadolPHASE1 · COMPLETED · started Jun 20, 2013ClinicalTrials.gov NCT03882762 · fetched Nov 12, 2026
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee PainPHASE2 · COMPLETED · started Dec 4, 2012ClinicalTrials.gov NCT01709214 · fetched Nov 12, 2026
Bunionectomy Trial With GRT6005PHASE2 · COMPLETED · started Mar 1, 2009ClinicalTrials.gov NCT00872885 · fetched Nov 12, 2026